ArticleBritish journal of cancer2025
Unveiling the impact of adherence: imatinib plasma levels and survival in postoperative gastrointestinal stromal tumor (GIST) patients.
Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic drug-monitoring-guided desensitization for severe imatinib-associated rash.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdherence to imatinib may be even more limited in the adjuvant setting, as patients receiving adjuvant imatinib often do not experience disease symptoms after tumor removal. This real-world study aimed to gain insight into adherence to imatinib and the effect of adherence on treatment outcomes.
methodsPostoperative GIST patients who visited the speciality clinic between January 2021 and September 2024 were included in the study.
resultsOut of 143 patients, 45 were non-adherent. The restricted mean survival time (RMST) at 3 years was measured for progression-free survival (PFS). Non-adherent patients had an RMST of 24.65 months, whereas adherent patients had an RMST of 32.66 months (P < 0.05). In addition, the plasma trough concentration of imatinib (C
conclusionsPoor adherence to imatinib was a notable problem in postoperative adjuvant treatment and appeared to be associated with shorter PFS. Monitoring trough levels gives physicians an objective measurement to assess individual adherence and can support treatment decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.